KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.

@article{Waters2018KRASTC,
  title={KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.},
  author={Andrew M. Waters and Channing J. Der},
  journal={Cold Spring Harbor perspectives in medicine},
  year={2018},
  volume={8 9}
}
  • Andrew M. Waters, C. Der
  • Published 1 September 2018
  • Biology, Medicine
  • Cold Spring Harbor perspectives in medicine
RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in human cancer. With the highest RAS mutation frequencies seen with the top three causes of cancer deaths in the United States (lung, colorectal, and pancreatic cancer), the development of anti-RAS therapies is a major priority for cancer research. Despite more than three decades of intense effort, no effective RAS inhibitors have yet to reach the cancer patient. With bitter lessons learned from past failures… 

Figures from this paper

Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma
TLDR
An updated summary of mutant KRAS role in the initiation, progression, and modulation of the TME of pancreatic ductal adenocarcinoma (PDAC) and the intriguing link between diabetes mellitus and PDAC is presented.
KRAS mutation in Pancreatic Cancer
TLDR
An updated summary of the understanding of mutant KRAS function in pancreatic cancer is presented and therapeutic strategies that target oncogenic KRAS signaling in this disease are discussed.
KRAS mutation in pancreatic cancer.
  • Ji Luo
  • Biology, Medicine
    Seminars in oncology
  • 2021
TLDR
An updated summary of the understanding of mutant KRAS function in pancreatic cancer is presented and therapeutic strategies that target oncogenic KRAS signaling in this disease are discussed.
Current Advances and Trends in KRAS Targeted Therapies for Colorectal Cancer
TLDR
The most recent scientific approaches and clinical trials targeting KRAS mutations directly or indirectly for the management of colorectal cancer are discussed.
Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
TLDR
This study presents an in-depth discussion of RAS proteins, classifies the RAS superfamily, and describes the molecular mechanism of small-molecule RAS inhibitors.
Targeting mutated GTPase KRAS in tumor therapies.
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
TLDR
Several different combination therapies for KRASmut cancer are being explored and if they hold the promise they have made in preclinical studies, they might also be suitable treatment options for patients suffering from PDAC.
Molecular epidemiology and diagnostics of KRAS mutations in human cancer
TLDR
RAS mutation is the most frequent oncogenic alteration in human cancers, followed by NRAS, and KRAS mutant cancers are characterized by typical, cancer-type-specific co-occurring mutations and distinct gene expression signatures.
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
TLDR
New avenues for investigating the potential of KRAS mutations on inflammatory TME modulation are expected to open, opening a different vision of therapeutic combined approaches to overcome KRAS-associated therapy inefficacy and resistance in cancer.
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
TLDR
An update is provided on knowledge of the vulnerability of the pancreas to KRAS-mediated invasive PDAC in the context of challenges engendered by obesity and associated inflammation.
...
...

References

SHOWING 1-10 OF 115 REFERENCES
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
TLDR
Using high-resolution magnetic resonance imaging to follow individual animals in longitudinal studies, it is shown that both primary and metastatic lesions depend on continuous Kras activity for their maintenance, but re-activation of Kras* following prolonged inactivation leads to rapid tumor relapse, raising the concern that Kras-resistance might eventually be acquired.
RAS isoforms and mutations in cancer at a glance
TLDR
A snapshot of the differences between RAS isoforms and mutations is provided, as well as the current status of anti-RAS drug-discovery efforts, matters that are current foci of ongoing research studies.
Drugging RAS: Know the enemy
TLDR
With a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered.
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
TLDR
Observations indicate that TBK1 and NF-κB signalling are essential in KRAS mutant tumours, and establish a general approach for the rational identification of co-dependent pathways in cancer.
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.
TLDR
It is established that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance, and strongly support the notion that inhibiting Krasg12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.
TLDR
It is shown that expression of BRAF(V600E), but not PIK3CA(H1047R), in the mouse pancreas leads to pancreatic intraepithelial neoplasia (PanIN) lesions, and RAF→MEK→ERK signaling is central to the initiation and maintenance of PDA and to rational combination strategies in this disease.
Genetically engineered mouse models of pancreatic cancer.
TLDR
The mouse models available, their experimental use, their clinical relevance and limitations, and future directions are reviewed, including in vivo models to study innovative and alternative treatment approaches are of major importance.
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.
TLDR
Deletion of the mouse Pak1 gene led to markedly decreased tumorigenesis and progression, accompanied by near total loss of Erk and Akt activity, establishing Pak1 as a new target in KRAS-driven tumors and suggesting a mechanism of action through the Erk, but not the Akt, signaling pathway.
...
...